Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boryung Pharmaceutical Co., Ltd
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who agree to participate in this study and give written informed consent
Subjects whose sitting diastolic blood pressure measured at placebo visit and baseline are more than 90 mmHg and/or systolic blood pressure are more than 140 mmHg
Subjects who are naive to anti-hypertensive treatment
Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study
You may not be if
Subjects who are hypersensitive to angiotensin type 1-receptor blockers
Subjects with secondary hypertension
Subjects with severe hypertension (systolic blood pressure \>= 180 mmHg OR diastolic blood pressure \>= 110)
Subjects with life expectancy of less than 2 years due to non-cardiac disease
Subjects with history or evidence of abuse of drugs or alcohol within 2 years
Severe insulin-dependent diabetes mellitus or intractable diabetic patient (dose/regimen change of oral hypoglycemic agent, insulin use)
Severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage, within 6 months)
Wasting diseases, autoimmune diseases (rheumatoid arthritis, systemic lupus anticoagulants, etc.), history of connective tissue disease or ongoing disease.
Women with pregnancy and breast feeding
Women planning to be pregnant or without admitted contraception despite of probability of pregnancy (Women who underwent sterilization operation are excluded. Fertile women without such surgery should undergo pregnancy test and can participate only with negative result. Intermittent abstinence like basic body temperature method, natural period method are not considered admitted contraception and no hormonal contraception is allowed.).
Subjects who are participating in other clinical trials for investigating agents or have taken other clinical trial medication within 4 weeks before screening visit.
Subjects judged to be inappropriate by the investigator
Clareo Health | Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion
